Introduction: Acute myeloid leukemia (AML) imposes significant burden on patients, their
INTRODUCTION
Acute myeloid leukemia (AML) is characterized by an overproduction of immature white blood cells in the bone marrow, which eventually spreads to the blood and sometimes other organs [1] . AML is a rare disease with incidence rates of 3-5 cases per 100,000 people in the United States (US) and Europe [2] and a life expectancy of 3-34 months [3] in newly-diagnosed patients. It is associated with significant treatment costs, placing a burden on the healthcare system [4] . However, the overall burden of illness on these patients and their families may be challenging to quantify.
In addition to being a rapidly progressing disease, AML appears to be quite symptomatic [2, [5] [6] [7] [8] , with the key signs/symptoms reported as dizziness, fatigue, fever, and weakness in literature [8] [9] [10] [11] . Furthermore, these signs/symptoms, along with the diagnosis of a life-threatening disease, have an impact on the patients' lives, including increased anxiety, fear, hopelessness, decreased ability to maintain social/familial roles, depression, low sex drive, and remission uncertainty, among others [7, [12] [13] [14] . The signs, symptoms, and impacts, collectively called 'concepts,' are also reflected in leukemia-specific patient-reported outcome (PROs) measure instruments, which contain a number of items for patients to complete [e.g., the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu)]. Currently, it is unknown whether the experience of AML varies considerably in patients across disease/treatment stages or whether there are cultural variations of concepts.
Thus, one PRO instrument may not fit all patients with AML, thereby making the measurement of the patient experience quite challenging.
To better understand this variability, we aimed at capturing the patient's experience of living with AML directly through qualitative interviews across two geographic locations, the US and Japan, and four different subgroups of patients with AML (newly-diagnosed, high-intensity chemotherapy; newly-diagnosed, low-intensity chemotherapy;
relapsed/refractory; post-transplant). These countries and groups were selected to align with the regions and treatment groups included in the ongoing Astellas clinical program. At the study initiation in September 2014, a literature review revealed there are no published studies on the experience of living with AML based on patients' interviews.
Thus, this study uniquely adds to our understanding of the experience of living with AML assessed from the patient's perspective. Specifically, we are now able to describe the disease using patient language, rather than being limited to our clinical/medical terminology, which reflects a unique point of view regarding AML.
METHODS

Participant Recruitment
Potential study participants in the US were recruited in two different ways: via advertisements on the internet at AML-specific online websites and forums, or from an existing online AML community. Advertisements were interactive; by clicking on a link, potential participants could learn more about the study and provide their email address to be contacted for screening and informed consent. Once an e-mail address was provided, an e-mail with a link was sent to the potential participant. If a potential participant opted to click on the link, he or she was directed to a site and asked to complete an online screening survey and provide electronic informed consent. Potential participants who were eligible for the study and provided informed consent were contacted for scheduling of an interview. Recruitment of patients with AML who were part of an existing online community and who had previously consented to be contacted for research purposes were contacted via e-mail; these patients were then screened and consented using the same methods as described above. The study was reviewed and approved by the Schulman Institutional Review Board in the US. Participants in Japan were recruited via clinicians who treat patients with AML.
Participants were screened for additional inclusion/exclusion criteria and for willingness and ability to participate. Consent was obtained from each participant prior to the interview. The subgroup criteria are summarized in Table 1 . Participants in both countries met the criteria for one of the following four subgroups:
• Newly-diagnosed participants receiving high-intensity chemotherapy treatment (chemotherapy that includes approximately 1-month hospitalization).
• Newly-diagnosed participants receiving low-intensity chemotherapy treatment (chemotherapy that involves short-term hospitalization with a less intensive, less toxic, or lower-dose approach). These patients were 65? years of age, as older patients are most likely unable to tolerate high-intensity chemotherapy.
• Relapsed/refractory participants. Relapsed participants were classified as achieving remission with their first chemotherapy, but symptoms have returned. Thus, these participants must undergo a second round of chemotherapy. Refractory participants were those who completed their second round of chemotherapy and in whom both the first and second rounds were unsuccessful in achieving remission. Relapsed/refractory participants could have been receiving high-or low-intensity treatment.
• Post-bone marrow or stem cell transplant participants were included in the transplant subgroup regardless of whether they were newly-diagnosed or considered relapsed/ refractory.
The sample size for the study was based on achieving 'saturation,' defined as the point at which no new relevant information emerges that would contribute to understanding the patient experience when assessed across all participants [15] . To determine saturation, the sample in each country was chronologically divided into three waves of relatively equal numbers of participants, such that waves could be compared for sign/symptom and impact similarity. A similar procedure was used to evaluate saturation within participant subgroups.
Participant Interview Procedures
Individual patient interviews were performed by telephone ranging from 60 to 75 minutes in duration. The interviews were recorded and then transcribed. The trained moderators who conducted the interviews followed an interview guide based on the information extracted from published literature on the signs, symptoms, and impacts of AML and its treatments and confirmed by clinicians [15] . In Japan, a third-party vendor translated all materials before conducting the interviews. The interviewers in Japan received 2 hours' training with the study's lead moderator to discuss the key objectives of the interview. Symptoms were defined to patients as ''any symptoms or sensations that you have experienced since being diagnosed with AML,'' 
RESULTS
Study Participants
A total of twenty-three US and eighteen Japanese participants were interviewed (Table 2) in the period between January 23 and March 11, 2014. The overall sample consisted of 37% males and 63% females; the median age of those interviewed was 48 years. There were fifteen newly-diagnosed high-intensity participants, nine newly-diagnosed low-intensity participants, nine relapse/refractory participants, and eight post-transplant participants.
Saturation was evaluated retrospectively after forty-one participant interviews. We found that none of the most frequently occurring signs/symptoms or impacts were added after the first interview wave (eight interviews) in the US and the first interview wave in Japan (six interviews). Thus, saturation had been achieved after fourteen participant interviews and additional interviews were conducted to ensure adequate sample sizes in each subgroup.
Forty-eight unique signs/symptoms and twenty-four unique impacts of AML and its treatments were mentioned by US participants (Tables S1 and S2 in the supplementary material), and thirty-one unique signs/symptoms and twenty-one unique impacts were mentioned by Japanese participants (Tables S3 and S4 in the supplementary material). The most frequently mentioned signs/symptoms and impacts in each participant subgroup were the same as those mentioned in the overall participant sample (Tables S1-S4 ). By way of example, the most frequently mentioned sign/symptom in the US, fatigue, was reported by 10/10 newly-diagnosed, high-intensity participants, 4/4 newly-diagnosed, low-intensity participants, 3/3 relapse/refractory participants, and 5/6 post-transplant participants.
In Japan, nausea was the most frequently mentioned sign/symptom and was reported by 5/5 newly-diagnosed, high-intensity participants, 4/5 newly-diagnosed, low-intensity participants, 6/6 relapse/refractory participants, and 2/2 post-transplant participants. Given the similarity of signs/symptoms and impacts reported in each of the subgroups, the results presented below will focus on comparisons and contrasts by region.
Here we present the signs/symptoms and impacts reported by at least 30% of participants in each subgroup and by 50% of the overall participant population. Signs/symptoms or impacts reported by less than 30% of any participant subgroup and by less than 50% of the overall population are included in the tables in the supplementary material.
Signs/Symptoms and Their Disturbance Effect on Participants' Lives
The most commonly reported sign/symptom in the US sample was fatigue (95.7%; Fatigue, fever, infection, nausea, and headache were the symptoms most often mentioned spontaneously by at least half of the respondents.
The most commonly reported symptom in the overall Japanese population was nausea (94.4%; Table 4 participants were for signs/symptoms of fatigue, fever, infection, and mouth sores (scores of 7-8), followed by those for weakness, diarrhea, dizziness, nausea, shortness of breath, bleeding, headache, swollen/bleeding gums, and poor healing (scores of 5-6). A US patient described his fever and stated, ''For about 3 days, I was having this fever and heart rates of about 150 beats per minute. And just felt awful, along with the rapid weight gain. The fever wasn't responding to Tylenol, which was the only thing that they could give me because I had leukemia. I ended up having to be packed in ice packs about every 2 hours for about 3 days straight.'' Another patient commented on his increased risk of infection noting, ''I have susceptibility to infection. With the immune suppression medication, I also don't want to be around crowds if I can avoid it because people equal sickness. The treatment, the immune suppression therapy is a big problem.''
The highest median disturbance ratings (range 0-10) for Japan participants were sign/ symptom concepts of shortness of breath (score of 9), fatigue, weakness, infection, and pain (scores of 8 for all), headache and cardiovascular problems (scores of 7), and bleeding, dizziness, fever, and anemia (scores of 5-6). A Japanese patient described fatigue stating, ''In the office fatigue was like less physical strength. I felt like I have suddenly aged 20 years.''
Impacts and Their Disturbance Effect on Participants' Lives
The most commonly reported impact in the overall US sample was a decreased ability to maintain social/familial roles, with 91.3% of participants reporting the concept during interviewing (Table 3) The impacts reported by C50% of the US sample included anxiety, decreased ability to function, financial difficulties, memory loss, problems concentrating, depression, fear, weight loss, remission uncertainty, and appetite loss.
Those concepts spontaneously reported by at least half of the respondents included decreased ability to maintain social/familial roles and decreased ability to function. A US participant described decreased ability to function as, ''I couldn't continue the work I used to do. I used to a Core concepts are defined as those reported by C50% of participants b Ratings based on a 0-10 scale (0 does not disturb, 10 greatly disturbing) Fig. 1 US acute myeloid leukemia patient symptoms and disturbance ratings from qualitative patient interview data The highest median disturbance ratings (range 0-10) for US participants were impact concepts of financial difficulties and depression (scores of 9 for both). A US participant noted that, ''It was more just that you're sitting around doing nothing. Couldn't work. Couldn't go anywhere. Not feeling good. I don't think it was bad, but I guess I probably was depressed at times, yeah.'' These were followed by decreased ability to maintain social/familial roles, decreased ability to function, anxiety, fear, remission uncertainty, and appetite loss (scores of 7-8), problems concentrating and memory loss (scores of 5-6). The highest median disturbance ratings for Japanese participants (range 0-10) were impact concepts of remission uncertainty and risk of other cancer (scores of 10 for both). These were followed by decreased ability to maintain social/familial role (scores of 7-9), anxiety, decreased ability to function, financial difficulties, fear, and problems concentrating Although this study was developed in line with the accepted methodology for this type of research, the sample size was relatively small, resulting in variability in the number of participants per subgroup. Such variability in sample size may explain some of the differences in the relative frequency of concept reporting between the US and Japan participants. We evaluated saturation within country and subgroups and found that it was reached (i.e., no new information was reported after the first wave of interviews). Therefore, in the context of relatively small sampling of subjects, we observed a high degree of consistency in patients' feedback.
In addition, patients from the US and Japan were recruited using different methods. Patients in Japan were clinically confirmed with their diagnosis of AML, whereas patients in the US self-reported their diagnosis. This may result in patients in the US misclassifying their condition. However, we do not believe this occurred as patients were recruited from AML internet sites, were screened appropriately, and confirmed their diagnosis during the interview.
Demographics and clinical characteristics, including comorbidities and details on treatments and concomitant medications,
were not collected as part of this study. This may be a limitation to the interpretation of the concepts due to confounding effects-the concepts reported may not necessarily be attributed to the disease, but rather to pre-existing comorbidities or medication side-effects. Although we acknowledge this limitation, we believe this did not significantly impact our findings since major comorbidities such as congestive heart failure, major infections, and hepatic impairment were screened for and there was a consistency in concepts reported among the four different treatment groups. Finally, most patients could not attribute whether symptoms were related to disease or treatment (e.g., fatigue was a result of AML but was worsened by treatment). While patients were able to describe their symptoms prior to and during treatment, they generally were unable to assess whether changes to the symptoms were a result of the disease worsening or a result of treatment side-effects.
Despite these limitations, the frequency and disturbance of a core set of signs/symptoms (e.g., fatigue, nausea, and shortness of breath) and impacts (e.g., anxiety and remission 
